In the last decade, plasma cardiac troponin T (cTnT) and cardiac troponin I (cTnI) have been identified as specific and sensitive markers of myocardial cell injury (1, 2 ) . During most types of cardiac surgery, some degree of myocardial injury regularly occurs that is dependent on multiple factors, such as the type and extent of the surgical procedure, the method of myocardial protection, the preoperative cardiac status of the patient, and the anesthetic procedures (3, 4 ) . In recent years, minimally invasive direct coronary artery bypass grafting (MID-CAB) and off-pump coronary artery bypass grafting (OP-CAB) have been introduced as alternative methods to coronary artery bypass grafting (CABG) (5 ). The potential advantages of MIDCAB and OPCAB arise from the avoidance of cardiopulmonary bypass (CPB) and cardioplegia. CPB always induces a systemic inflammatory response syndrome, and a substantial number of patients develop multiple organ dysfunction. However, there are also disadvantages of MIDCAB and OPCAB, including difficulty of performing the coronary anastomosis on the beating heart, ischemic damage during occlusion of the targeted vessel, and cardiac dislocation or compression to obtain optimal exposure of the vessels on the posterior wall. Currently, only limited data (6 -9 ) concerning the release of troponins during MIDCAB and OPCAB are available.
In the last decade, plasma cardiac troponin T (cTnT) and cardiac troponin I (cTnI) have been identified as specific and sensitive markers of myocardial cell injury (1, 2 ) . During most types of cardiac surgery, some degree of myocardial injury regularly occurs that is dependent on multiple factors, such as the type and extent of the surgical procedure, the method of myocardial protection, the preoperative cardiac status of the patient, and the anesthetic procedures (3, 4 ) . In recent years, minimally invasive direct coronary artery bypass grafting (MID-CAB) and off-pump coronary artery bypass grafting (OP-CAB) have been introduced as alternative methods to coronary artery bypass grafting (CABG) (5 ) . The potential advantages of MIDCAB and OPCAB arise from the avoidance of cardiopulmonary bypass (CPB) and cardioplegia. CPB always induces a systemic inflammatory response syndrome, and a substantial number of patients develop multiple organ dysfunction. However, there are also disadvantages of MIDCAB and OPCAB, including difficulty of performing the coronary anastomosis on the beating heart, ischemic damage during occlusion of the targeted vessel, and cardiac dislocation or compression to obtain optimal exposure of the vessels on the posterior wall. Currently, only limited data (6 -9 ) concerning the release of troponins during MIDCAB and OPCAB are available.
The aim of this investigation was to study the effect of different surgical techniques, using a latest generation assay for the determination of cTnT, and to compare cTnI results to cTnT, particularly for diagnostic sensitivity.
Twenty-six consecutive patients (8 women and 18 men; median age, 63 years; range, 40 -76 years; 25th-75th percentile, 52-69 years) were entered in the prospective study after giving informed consent. Twenty-one patients had a single left internal mammary artery graft to the left anterior descending artery through a left anterior small thoracotomy (MIDCAB). Four patients with two-or threevessel disease also underwent operations without CPB but with a median sternotomy (OPCAB) using the Octopus stabilizer (Medtronic) or the CTS stabilizer (Cardio-Thoracic System). At the end of anastomosis, conversion to conventional CABG with use of CPB was necessary in one patient (patient 17). Perioperative myocardial infarction (PMI) was diagnosed when the following criteria were satisfied: (a) creatinine kinase MB isoenzyme activity Ͼ50 U/L [immunoinhibition assay based on optimized standard method (25°C) of the German Society of Clinical Chemistry]; and (b) the appearance of new Q-waves or a reduction of R-waves in two or more contiguous leads.
Blood samples were collected into ammonium heparinate tubes (Sarstedt) before (sample T1) and immediately after (sample T2) revascularization. Additional samples were drawn 2 (sample T3), 3 (sample T4), and 4 (sample T5) h after revascularization and at 0600 daily thereafter (samples T6 -T12, depending on length of hospital stay). After centrifugation, aliquots were stored frozen at Ϫ30°C until assayed in batches.
The third-generation cTnT assay was performed in an Elecsys ® 1010 instrument (Roche Diagnostics, Mannheim, Germany). cTnI was measured with the AxSYM ® -System (Abbott Laboratories). The detection limits of the assays were 0.01 g/L for cTnT and 0.3 g/L for cTnI. The upper reference limit for apparently healthy individuals is 0.04 g/L for cTnT (10 ) and 0.5 g/L for cTnI (11 ) . The general decision limits for acute myocardial infarction (suggested cutoffs, 0.2-0.5 g/L for cTnT and 2.0 g/L for cTnI) are not valid after cardiac surgery. Uncomplicated cases have a median cTnT at the first postoperative day of 0.29 g/L (5th percentile, 0.11 g/L; 95th percentile, 1.68 g/L) after conventional CABG in our institution.
The within-run imprecision using a patient's sample was 3.58% (mean, 0.091 g/L; range, 0.088 -0.097 g/L; n ϭ 10) for cTnT vs 30.6% (mean, 0.45 g/L; range, 0.3-0.7 g/L; n ϭ 7) for cTnI. The between-run imprecision using "low-end" control material was 13.7% for cTnT (PCcard1 control; mean cTnT, 0.15 g/L; n ϭ 6) and 9.6% for the cTnI (AxSYM low control; mean, 4.2 g/L; n ϭ 20). A total of 241 specimen from 26 patients were analyzed. Fig. 1 shows the concentrations of cTnT ( Fig. 1A ) and of cTnI ( Fig. 1B) at the different sampling points; the line represents the medians, which were Ͻ0.1 g/L for cTnT and Ͻ1.0 g/L for cTnI at all sampling times. The peak concentrations are listed in Table 1 . The comparison of cTnT and cTnI results showed clinically congruent results in most patients. Discrepancies in the relative increase of troponin were found in only one patient (patient 9), who had no clinical complications. The very low peak cTnT of 0.09 g/L seems more plausible than the peak cTnI of 5.2 g/L. The maximum cTnI concentrations in the two PMI patients (patients 11 and 20) were far above the highest cTnI values of uncomplicated cases. Currently in most institutions, patients selected for MIDCAB have mostly one-vessel disease. Therefore, comparisons of postoperative troponin concentrations in patients after MIDCAB operation with conventional CABG, where often more than three vessels are grafted, must be looked on with some reservations. After conventional CABG, a substantial postoperative increase of troponins occurs regularly (4 ) . This is in contrast to our MIDCAB patients; we had five patients with undetectable cTnT. Only slight increases of cTnT in the range 0.01-0.1 g/L were found in 10 patients. cTnI was below the detection limit in six patients.
In conclusion, we found that cTnT (Elecsys) as well as cTnI (AxSYM) concentrations in plasma of patients after MIDCAB and OPCAB operations were undetectable in 20% of the cases studied and were only slightly increased in most other patients. Compared with conventional CABG, this indicates less myocardial damage and demonstrates the safety of the applied techniques.
Both troponin assays generate generally comparable results.
We thank Roche Diagnostics for providing the Elecsys instrument. The lines represent the median troponin values at each sampling point. For better visualization of the results at very low concentrations, a logarithmic scale was used. Sample T1 was drawn immediately before revascularization; sample T2 was drawn immediately after revascularization. Samples T3-T5 were drawn 2, 3, and 4 h after revascularization, respectively; samples T6 -T12 were drawn at 0600 daily thereafter. (4, 5 ) .
One reference method is based on liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) of the ␤-N-terminal hexapeptides of HbA 1c and HbA 0 obtained by enzymatic cleavage of the intact hemoglobin (Hb) molecule with endoproteinase Glu-C (5 ) . The method has been demonstrated as reliable in intercomparison studies (6 ) , but it has a relatively long analysis time (total cycle time of the HPLC program is 24 min). The LC part of the method utilizes a 150 ϫ 2.1 mm Zorbax ® SB-CN column (5 m bead size; 80 Å pore size) in the reversed-phase mode with a water-acetonitrile gradient (both containing ϳ0.23 mL/L trifluoroacetic acid). For ESI-MS detection, it makes use of the single-ion recording (SIR) mode of the [Mϩ2H] ϩ ions at m/z 348 and 429. We aimed to reduce the analysis time by use of a C 18 reversed-phase HPLC system with a shorter gradient program. We performed experiments with this column and its chromatographic conditions, and with MS detection in the SIR and multiple-reaction monitoring (MRM) modes. We investigated the latter in particular despite some earlier reports (7, 8 ) because it could compensate for any loss in chromatographic performance.
We used remaining aliquots (stored at Ϫ80°C) of patient specimens and primary calibrators used previously by the IFCC Working Group in an intercomparison study of the existing LC-ESI-MS (SIR mode) reference method (5 ) . For sample pretreatment, we used the adapted standard procedure for the reference method (5, 6 ) . In short, it consisted of hemolysis of EDTA blood, digestion of the hemolysate (representing ϳ1 mg of total Hb) with endoproteinase Glu-C in 50 mmol/L ammonium acetate buffer (adjusted to pH 4.3 with acetic acid), and freezing at Ϫ20°C to stop the enzymatic activity. For the calibrators (also containing ϳ1 mg total Hb and different percentages of HbA 1c ), we used the same digestion procedure as described for the sample hemolysates. For injection into the HPLC system, we used 10 L of the digest. The HPLC inlet system to the mass spectrometer used a pump system (model 325) and a water-cooled (8°C) autosampler 465 (Kontron). Chromatography used a C 18 guard column (Nucleosil ® ; 11 ϫ 2 mm; 5 m bead size; 300 Å pore size; Macherey-Nagel) at 50°C with a flow rate of 0.5 mL/min. The gradient program (cycle time, 8 min) used 100% eluent A (0.3 mL/L formic acid in water) for 0.5 min, with eluent B (0.3 mL/L formic acid in methanol) increased from 0% to 10% over the next 0.1 min, held constant for 3.1 min, and increased to 100% over the next 0.1 min; the system was held at 100% B for the next 1.1 min, returned to 100% eluent A over the next 0.1 min, and then reequilibrated in 100% eluent A for 3 min. The HPLC flow was switched out of the mass spectrometer between 4.7 and 7.0 min by use of an electrically actuated Valco valve.
A VG Quattro II mass spectrometer from Micromass, equipped with an electrospray interface, was used for quantitative mass spectrometric detection in the positive ionization tandem MS mode, with argon as the collision gas. For SIR, we monitored the same ions (m/z 348 and 429) under the same mass spectrometric conditions as for the reference method (5 ) . For MRM, we used the doubly charged precursor and singly charged product ion pairs Clinical Chemistry 46, No. 2, 2000 
